Alpha Sense BI

MAY 28, 2024

Below, we explore the factors constraining venture capital funding into the first half of the year, and the ways investors can leverage crucial market intelligence to gain a competitive advantage in the shifting landscape. Start your free trial today and accelerate your investment research.

Capital 69

Capital Startups Biotech Due Diligence 69

Alpha Sense BI

FEBRUARY 8, 2023

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.

Biotech 96

Biotech Research Innovation Capital 96

Alpha Sense BI

APRIL 29, 2024

The Transformative Effect of Generative AI By 2025, it is estimated that more than 75% of venture capital (VC) and early-stage investor executive reviews will be informed using artificial intelligence (AI) and data analytics. There is no doubt that generative AI has emerged as a powerful tool in the investment space.

Capital 52

Capital Due Diligence Biotech Startups 52

Netbasequid

FEBRUARY 22, 2021

In their paper on Deep Tech: The Great Wave of Innovation , BCG and Hello Tomorrow explain “what deep tech is, how it works, how different stakeholders can contribute to it, and how it can be harnessed for competitive advantage.” And they used NetBase Quid to inform their research. From here, the biotech world is your oyster.

Biotech 98

Biotech Innovation Intellectual Property Market Research 98

Alpha Sense BI

AUGUST 30, 2023

As time goes on and more firms adopt AI tools, these capabilities will become even more essential to maintain a competitive advantage. Research shows that the AI in asset management market will grow at a staggering 34% CAGR through 2027. Artificial intelligence is the only way to do it.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

JANUARY 25, 2023

Moderna and BioTech, the pharmaceuticals companies behind the Moderna vaccines for the COVID-19 virus, just announced a new treatment this past December that would greatly reduce the chances of death from melanoma — stirring up substantial interest in investors to funnel capital. a potential cure for skin cancer.

Biotech 96

Biotech Pharmaceutical Hospitals Market Intelligence 96

Sedulo

MARCH 15, 2023

As leaders in competitive strategy consulting, serving the life sciences community for the last 17 years, Sedulo Group can help you: Build a comprehensive view of the current and future competitive landscape. Obtain details on competitor clinical trial locations. Assess and benchmark enrollment timing.

Biotech 52

Biotech Competitive Landscape Pharmaceutical Benchmarking 52